ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.63
0.12%
US Tech 100
21,156.80
-0.70%
S&P 500
6,101.24
-0.29%
US Dollar vs CAD
1.43838
-0.72%
Bitcoin
99,430.75
-3.15%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Compugen Ltd (CGEN)

  7. Compugen Ltd (CGEN) News

CGEN

Compugen (CGEN)

Compugen Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CGEN
DateTimeSourceHeadlineSymbolCompany
01/08/20256:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
01/08/20256:00AMPR Newswire (US)Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsNASDAQ:CGENCompugen Ltd
11/27/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
11/27/20246:00AMPR Newswire (US)Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNASDAQ:CGENCompugen Ltd
11/12/20246:00AMPR Newswire (US)Compugen Reports Third Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
11/11/20246:00AMPR Newswire (US)Compugen to Participate in Stifel 2024 Healthcare ConferenceNASDAQ:CGENCompugen Ltd
11/05/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
11/05/20248:00AMPR Newswire (US)Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024NASDAQ:CGENCompugen Ltd
10/29/20246:00AMPR Newswire (US)Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:CGENCompugen Ltd
10/07/20246:00AMPR Newswire (US)Compugen to Present New Clinical Data at SITC 2024NASDAQ:CGENCompugen Ltd
09/13/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
09/09/20246:00AMPR Newswire (US)Compugen to Present at Single Cell Genomics 2024 ConferenceNASDAQ:CGENCompugen Ltd
08/29/20246:00AMPR Newswire (US)Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CGENCompugen Ltd
08/06/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
08/06/20246:00AMPR Newswire (US)Compugen Reports Second Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
08/05/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
07/29/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
07/29/20246:00AMPR Newswire (US)Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsNASDAQ:CGENCompugen Ltd
07/23/20246:00AMPR Newswire (US)Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024NASDAQ:CGENCompugen Ltd
06/17/20246:00AMPR Newswire (US)Compugen to Present at Upcoming Antibody Industrial SymposiumNASDAQ:CGENCompugen Ltd
05/30/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
05/30/20246:00AMPR Newswire (US)Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigNASDAQ:CGENCompugen Ltd
05/20/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
05/20/20246:00AMPR Newswire (US)Compugen Reports First Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
05/20/20245:59AMIH Market NewsU.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices DipNASDAQ:CGENCompugen Ltd
05/16/20246:00AMPR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic PotentialNASDAQ:CGENCompugen Ltd
05/15/20246:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
05/15/20246:00AMPR Newswire (US)Compugen Appoints David Silberman as Chief Financial OfficerNASDAQ:CGENCompugen Ltd
05/06/20246:00AMPR Newswire (US)Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024NASDAQ:CGENCompugen Ltd
04/25/20246:00AMPR Newswire (US)Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024NASDAQ:CGENCompugen Ltd
 Showing the most relevant articles for your search:NASDAQ:CGEN

Your Recent History

BIT
P1J7A7
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads